Back to search

Article

Decoding HRD: A Genomic LOH-Based Assay Associated With Platinum Response and Survival in High-Grade Serous Ovarian Cancer

2026-04-07

Abstract excerpt

<title>Abstract</title> <p> Homologous recombination deficiency (HRD) is a clinically relevant biomarker associated with therapeutic response to platinum-based chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors in high-grade serous ovarian cancer (HGSOC). We evaluated an NGS-based HRD assay integrating <italic>BRCA1/2</italic> mutation detection with genomic loss of heterozygosity (gLOH) using 90 H...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
85ec5d79-4fcf-5871-ae4c-f9f47cbbc733
DOI
10.21203/rs.3.rs-9243705/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Decoding HRD: A Genomic LOH-Based Assay Associated With Platinum Response and Survival in High-Grade Serous Ovarian CancerDOI 10.21203/rs.3.rs-9243705/v1
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerSemantic proximity
Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.Semantic proximity
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity
Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity
Benchmarking homologous recombination deficiency algorithms for prediction of clinical outcome in ovarian cancerSemantic proximity
Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.Semantic proximity
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Semantic proximity
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity
Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization ProjectSemantic proximity
Select a neighboring publication to make it the new centre.